Rivaroxaban

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

2008

www.ebi.ac.uk

First approval year: 2008
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Rivaroxaban
www.ebi.ac.uk

Molecular weight: 435.89
www.ebi.ac.uk

Structure (SMILES): O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
www.ebi.ac.uk

rivaroxaban accord
Rivaroxaban accord
Rivaroxaban viatris (previously rivaroxaban mylan)
rivaroxaban viatris previously rivaroxaban mylan
xarelto
Xarelto

(S)-Rivaroxaban
20 mg tablet rivaroxaban
bay 59 7939
BAY 59-7939
BAY-59-7939
bay59 7939
BAY59-7939
Drug: Rivaroxaban
jnj 39039039
JNJ-39039039
jnj39039039
JNJ39039039
rivaroxaban
Rivaroxaban
rivaroxaban (10mg)
Rivaroxaban (15 mg)
Rivaroxaban (20 mg)
Rivaroxaban (ATC B01AF01)
Rivaroxaban (BAY 59-7939)
Rivaroxaban (BAY59-7939)
Rivaroxaban (BAY59-7939) suspension
Rivaroxaban (normal renal function)
Rivaroxaban (Xarelto)
Rivaroxaban [EMA EPAR]
Rivaroxaban [EP MONOGRAPH]

And 63 more, listed on the interactive page.

ATC classification codes

B01AF01

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

366789-02-8

ChEMBL ID: CHEMBL198362
www.ebi.ac.uk

InChIKey: KGFYHTZWPPHNLQ-AWEZNQCLSA-N
www.ebi.ac.uk

PubChem compound IDs

9875401

RxNorm IDs (RxCUI)

1114195

FDA ingredient codes (UNII)

9NDF7JZ4M3

Applicant: JANSSEN PHARMS
Approval date: 1 Jul 2011
Application number: NDA022406

Status: Authorised
Status date: 30 Sept 2008
Authorisation date: 30 Sept 2008
Approved indications: Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers. Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events. Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. Adults Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ? 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
Product number: EMEA/H/C/000944
Authorisation holder: Bayer AG
Priority medicines scheme: No
Generic: No
Biosimilar: No
Generic medicines: 3
Biosimilar medicines: 0
Advanced therapy: No
Conditional approval: No
Additional monitoring: No
Accelerated assessment: No
Exceptional circumstances: No

Therapeutic areas

Arthroplasty, Replacement
Venous Thromboembolism

European medicines record

www.ema.europa.eu

Patents: 2
Designations: 0
Earliest recorded loss of exclusivity: 17 Aug 2034
First in class: Yes
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: No
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only
Boxed warning: Yes

Pharmacology name: rivaroxaban
Type: Synthetic organic
Drug name stem: -xaban
Approval recorded by Guide to Pharmacology: Yes

Administration routes

Oral

Action
Inhibition
Action type
Inhibitor
Target
coagulation factor X
Gene symbol
F10
Protein identifier
P00742
Median affinity
9.4
Affinity units
pKi
Primary target
Yes
Mechanism
Coagulation factor X inhibitor
Action type
Inhibitor
Target
Coagulation factor X
Protein identifier
P00742

Open Targets mechanisms

Mechanism
Coagulation factor X inhibitor
Action type
Inhibitor
Target
Coagulation factor X

DrugCentral mechanisms

Action type
Inhibitor
Gene symbol
F10
Protein identifier
P00742
Organism
Homo sapiens
Target development level
Clinical

Condition
Aortic Valve Stenosis
Highest recorded phase
3
Condition identifier
EFO:0000266
Subject identifier
D001024
Condition
Atrial Fibrillation
Highest recorded phase
4
Condition identifier
EFO:0000275
Subject identifier
D001281
Condition
Ischemia
Highest recorded phase
2
Condition identifier
EFO:0000556
Subject identifier
D007511
Condition
Myocardial Infarction
Highest recorded phase
3
Condition identifier
EFO:0000612
Subject identifier
D009203
Condition
Neoplasms
Highest recorded phase
3
Condition identifier
EFO:0000616
Subject identifier
D009369
Condition
Severe Acute Respiratory Syndrome
Highest recorded phase
3
Condition identifier
EFO:0000694
Subject identifier
D045169
Condition
Stroke
Highest recorded phase
4
Condition identifier
EFO:0000712
Subject identifier
D020521
Condition
Obesity, Morbid
Highest recorded phase
1
Condition identifier
EFO:0001074
Subject identifier
D009767
Condition
Multiple Myeloma
Highest recorded phase
2
Condition identifier
EFO:0001378
Subject identifier
D009101
Condition
Liver Cirrhosis
Highest recorded phase
3
Condition identifier
EFO:0001422
Subject identifier
D008103
Condition
Coronary Artery Disease
Highest recorded phase
4
Condition identifier
EFO:0001645
Subject identifier
D003324
Condition
Heart Diseases
Highest recorded phase
2
Condition identifier
EFO:0003777
Subject identifier
D006331
Condition
Pulmonary Embolism
Highest recorded phase
4
Condition identifier
EFO:0003827
Subject identifier
D011655
Condition
Renal Insufficiency, Chronic
Highest recorded phase
1
Condition identifier
EFO:0003884
Subject identifier
D051436
Condition
Venous Thrombosis
Highest recorded phase
4
Condition identifier
EFO:0003907
Subject identifier
D020246
Condition
Hip Fractures
Highest recorded phase
3
Condition identifier
EFO:0003964
Subject identifier
D006620
Condition
Peripheral Arterial Disease
Highest recorded phase
4
Condition identifier
EFO:0004265
Subject identifier
D058729
Condition
Venous Thromboembolism
Highest recorded phase
4
Condition identifier
EFO:0004286
Subject identifier
D054556
Condition
Acute Coronary Syndrome
Highest recorded phase
4
Condition identifier
EFO:0005672
Subject identifier
D054058
Condition
Blood Coagulation Disorders
Highest recorded phase
1
Condition identifier
EFO:0009314
Subject identifier
D001778
Condition
Aortic Valve Disease
Highest recorded phase
2
Condition identifier
EFO:0009531
Subject identifier
D000082862
Condition
Hematoma
Highest recorded phase
3
Condition identifier
EFO:0010680
Subject identifier
D006406
Condition
Arthroplasty, Replacement
Highest recorded phase
4
Condition identifier
EFO:0010726
Subject identifier
D019643
Condition
Angina, Unstable
Highest recorded phase
3
Condition identifier
EFO:1000985
Subject identifier
D000789
Condition
Rheumatic Heart Disease
Highest recorded phase
3
Condition identifier
EFO:1001161
Subject identifier
D012214

And 13 more, listed on the interactive page.

Condition identifier
EFO_0000266
Highest recorded phase
3
Condition identifier
EFO_0000275
Condition identifier
EFO_0000538
Highest recorded phase
3
Condition identifier
EFO_0000551
Highest recorded phase
3
Condition identifier
EFO_0000612
Highest recorded phase
3
Condition identifier
EFO_0000616
Highest recorded phase
3
Condition identifier
EFO_0000712
Condition identifier
EFO_0001074
Highest recorded phase
1
Condition identifier
EFO_0001422
Highest recorded phase
3
Condition identifier
EFO_0001645
Condition identifier
EFO_0002689
Condition identifier
EFO_0003144
Highest recorded phase
3
Condition identifier
EFO_0003827
Condition identifier
EFO_0003884
Highest recorded phase
1
Condition identifier
EFO_0003907
Condition identifier
EFO_0003907
Highest recorded phase
4
Condition identifier
EFO_0003964
Highest recorded phase
2
Condition identifier
EFO_0004265
Condition identifier
EFO_0004286
Condition identifier
EFO_0005672
Condition identifier
EFO_0008585
Highest recorded phase
3
Condition identifier
EFO_0009806
Condition identifier
EFO_0010680
Highest recorded phase
3
Condition identifier
EFO_0010726
Condition identifier
EFO_0010726
Highest recorded phase
4

And 57 more, listed on the interactive page.

Warnings

Warning
Black Box Warning
Effect
vascular toxicity

Open Targets warnings

Warning
Black Box Warning
Effect
vascular toxicity
Country
United States

Event
anaemia
Reports
2,136
Reporting signal score
705.57
Event
atrial thrombosis
Reports
430
Reporting signal score
1,015.81
Event
cerebral haemorrhage
Reports
997
Reporting signal score
1,486.99
Event
cerebral infarction
Reports
1,212
Reporting signal score
1,780.71
Event
cerebrovascular accident
Reports
2,365
Reporting signal score
1,865
Event
deep vein thrombosis
Reports
3,221
Reporting signal score
4,703.82
Event
embolic stroke
Reports
408
Reporting signal score
853.731
Event
epistaxis
Reports
1,835
Reporting signal score
2,081.35
Event
fatigue
Reports
683
Reporting signal score
688.652
Event
gastrointestinal haemorrhage
Reports
5,556
Reporting signal score
10,642.8
Event
haematoma
Reports
983
Reporting signal score
1,220.84
Event
haematuria
Reports
1,538
Reporting signal score
2,112.73
Event
haemoglobin decreased
Reports
1,674
Reporting signal score
969.209
Event
haemorrhage
Reports
2,122
Reporting signal score
2,321.22
Event
haemorrhage intracranial
Reports
774
Reporting signal score
1,301.32
Event
injection site pain
Reports
9
Reporting signal score
709.754
Event
ischaemic stroke
Reports
1,133
Reporting signal score
1,773.12
Event
lower gastrointestinal haemorrhage
Reports
471
Reporting signal score
854.87
Event
melaena
Reports
902
Reporting signal score
1,099.29
Event
nausea
Reports
821
Reporting signal score
743.837
Event
pain
Reports
264
Reporting signal score
722.216
Event
pulmonary embolism
Reports
3,140
Reporting signal score
4,016.29
Event
rectal haemorrhage
Reports
1,057
Reporting signal score
1,184.21
Event
thrombosis
Reports
1,328
Reporting signal score
1,144.37
Event
upper gastrointestinal haemorrhage
Reports
932
Reporting signal score
1,648.59

NCT00329628
clinicaltrials.gov
NCT00332020
clinicaltrials.gov
NCT00361894
clinicaltrials.gov
NCT00362232
clinicaltrials.gov
NCT00395772
clinicaltrials.gov
NCT00396786
clinicaltrials.gov
NCT00398905
clinicaltrials.gov
NCT00402467
clinicaltrials.gov
NCT00439725
clinicaltrials.gov
NCT00571649
clinicaltrials.gov
NCT01205932
clinicaltrials.gov
NCT01206972
clinicaltrials.gov
NCT01210755
clinicaltrials.gov
NCT01344954
clinicaltrials.gov
NCT01431456
clinicaltrials.gov
NCT01720108
clinicaltrials.gov
NCT02234843
clinicaltrials.gov
NCT02271399
clinicaltrials.gov
NCT02309411
clinicaltrials.gov
NCT02438098
clinicaltrials.gov
NCT02559856
clinicaltrials.gov
NCT02583191
clinicaltrials.gov
NCT02829957
clinicaltrials.gov
NCT02832947
clinicaltrials.gov
NCT03055026
clinicaltrials.gov

And 108 more, listed on the interactive page.

Dose: 5 mg
Route: Oral
How often: Once daily

Conditions of use

Take with food

Hydrogen bond acceptors: 6
Hydrogen bond donors: 1
Polar surface area: 88.18
Calculated partition coefficient (ALogP): 2.52
Calculated partition coefficient (XLogP): 2.5
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 0
Rotatable bonds: 5
Heavy atoms: 29
Molecular formula: C19H18ClN3O5S
Monoisotopic mass: 435.0655696
Natural product: Yes

14445-147
14445-148
14445-183
14445-184
31722-496
33342-488
42571-345
43598-981
46708-240
46708-346
46708-347
46708-348
46708-683
50228-513
50458-575
50458-577
50458-578
50458-579
50458-580
50458-584
59651-849
62332-240
62332-346
62332-347
62332-348

And 21 more, listed on the interactive page.

Recorded assays: 388
Active assays: 47

Confirmatory
Other

Factor Xa Inhibitors
id.nlm.nih.gov

Oral bioavailability

Median: 60
Mean: 58.8571
Minimum: 21.3
Maximum: 86
Unit: %
Assays: 7
Standard deviation: 19.3116
Summary method: median
Censored results excluded: 0
Other units excluded: 0
Unknown units excluded: 0

Measurement types

Related records

Trials (507)

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa
A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
A New Oral Treatment For Type II Diabetes Mellitus
A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer
A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma
A Prospective Pharmacodynamic Study of Rivaroxaban
A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects
A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
A Study of BGM0504 Injection in Participants with Obesity or Overweight
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Approved for (8)

In development for (25)

Aortic valve disorder Phase 2
Aortic valve stenosis Phase 3
Autoimmune polyendocrinopathy Phase 3
Blood coagulation disease Phase 1
Cancer Phase 3
Chronic kidney disease Phase 1
Cirrhosis of liver Phase 3
COVID-19 Phase 3
Heart disorder Phase 2
Heart failure Phase 3
Hip fracture Phase 3
Hypertrophic cardiomyopathy Phase 3
Intermediate coronary syndrome Phase 3
Ischemic disease Phase 2
Ischemic stroke Phase 3
Kidney failure Phase 3
Morbid obesity Phase 1
Myocardial infarction Phase 3
Neoplasm Phase 3
Plasma cell myeloma Phase 2

Targets (1)

F10 Coagulation factor X inhibitor

Rivaroxaban

Development status

Names and chemistry

Brand names (6)

Other names (88)

Identifiers

Regulatory information

United States

European Union

Therapeutic areas

Other regulatory facts

Pharmacology

Drug classification

Administration routes

Mechanisms of action (2)

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (38)

Open Targets indications (82)

Warnings

Open Targets warnings

Reported adverse events (25)

Trial references (133)

Dosing

Conditions of use

Chemical properties

National Drug Codes

Evidence counts

Active assay types (2)

Pharmacologic actions

Biological measurements

Observed measurements

Oral bioavailability

Measurement types

Related records

Trials (507)

Approved for (8)

In development for (25)

Other linked conditions (3)

Targets (1)